Beijing, Sept 1, 2026 — China’s Center for Medical Device Evaluation (CMDE) released 16 draft registration and review guidelines for Class II in vitro diagnostic (IVD) reagents and medical devices, opening a public comment period through Oct 8, 2026, as regulators standardize market entry requirements for diagnostic testing products including parathyroid hormone assay reagents.
Regulatory Snapshot
| Attribute | Detail |
|---|---|
| Issuer | Center for Medical Device Evaluation (CMDE), National Medical Products Administration |
| Document | 16 Guiding Principles for Registration and Review of Class II In Vitro Diagnostic Reagents and Medical Devices (Draft for Comments) |
| Lead guideline | Parathyroid Hormone Assay Reagent Registration and Review Guiding Principles |
| Total guidelines | 16 |
| Product class | Class II in vitro diagnostic reagents and medical devices |
| Comment deadline | Oct 8, 2026 |
| Submission | Contact details per attached list |
Key Scope
The batch covers registration and review technical standards for 16 categories of Class II IVD reagents and devices. The lead document addresses parathyroid hormone assay reagents, with the full portfolio spanning diverse diagnostic testing categories.
Market Impact Analysis
The simultaneous release of 16 draft guidelines represents a significant standardization effort for mid-risk diagnostic products, creating a comprehensive regulatory roadmap for IVD manufacturers navigating China’s Class II registration pathway. For domestic and international diagnostic makers, the consolidated guidance reduces interpretive ambiguity during application preparation, potentially shortening registration timelines by clarifying technical documentation, performance evaluation, and clinical evidence requirements.
The Oct 8 comment deadline provides a five-week window for industry feedback, suggesting regulators aim to finalize the guidelines by year-end. The focus on Class II IVD reagents—a category that includes immunoassay kits, clinical chemistry reagents, and molecular diagnostic products—signals intensified scrutiny of diagnostic devices that are widely used in clinical laboratories but produced by a fragmented supplier base.
Forward-Looking Statement
Industry analysts expect the finalized 16 guidelines to take effect in early 2027, establishing the definitive regulatory baseline for Class II IVD registrations through the remainder of the decade. Manufacturers with pending applications or pipeline products in the covered categories should review the drafts closely, as final versions may introduce new analytical performance requirements or clinical validation standards not explicitly mandated under previous informal guidance. The bulk release approach suggests CMDE is moving toward systematic catalog-wide standardization rather than reactive, product-specific rulemaking, a shift that could accelerate overall review efficiency but demands proactive compliance monitoring across broad diagnostic portfolios.-China Health Reform Pulse
Policy Source: https://www.cmde.org.cn/flfg/zdyz/zqyjg/20260901133826130.html